PPARG and Insulin resistance: TZD, a PPARγ agonist, has been reported to decrease the blood glucose levels and ameliorate insulin resistance in diabetic animal model and patients and has been widely used in clinical practice (Saraf et al., 2012; Janani and Ranjitha Kumari, 2015).